相似文献
1
Prostate tumor development and androgen receptor function alterations in a new mouse model with ERG overexpression and PTEN inactivation.
Cancer Biol Ther. 2014 Oct;15(10):1293-5. doi: 10.4161/cbt.29694. Epub 2014 Jul 9.
2
ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss.
Nat Med. 2013 Aug;19(8):1023-9. doi: 10.1038/nm.3216. Epub 2013 Jun 30.
3
A step toward functionally characterized prostate cancer molecular subtypes.
Nat Med. 2013 Aug;19(8):966-7. doi: 10.1038/nm.3285.
4
ERF mutations reveal a balance of ETS factors controlling prostate oncogenesis.
Nature. 2017 Jun 29;546(7660):671-675. doi: 10.1038/nature22820. Epub 2017 Jun 14.
5
Modulation of androgen receptor DNA binding activity through direct interaction with the ETS transcription factor ERG.
Proc Natl Acad Sci U S A. 2020 Apr 14;117(15):8584-8592. doi: 10.1073/pnas.1922159117. Epub 2020 Mar 27.
6
ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells.
Proc Natl Acad Sci U S A. 2009 Jul 28;106(30):12465-70. doi: 10.1073/pnas.0905931106. Epub 2009 Jul 10.
7
COP1 is a tumour suppressor that causes degradation of ETS transcription factors.
Nature. 2011 May 15;474(7351):403-6. doi: 10.1038/nature10005.
8
Interaction of the Androgen Receptor, ETV1, and PTEN Pathways in Mouse Prostate Varies with Pathological Stage and Predicts Cancer Progression.
Horm Cancer. 2015 Jun;6(2-3):67-86. doi: 10.1007/s12672-014-0215-9. Epub 2015 Jan 29.
9
Suppression of CHK1 by ETS Family Members Promotes DNA Damage Response Bypass and Tumorigenesis.
Cancer Discov. 2015 May;5(5):550-63. doi: 10.1158/2159-8290.CD-13-1050. Epub 2015 Feb 4.
10
Interactions and relationships of PTEN, ERG, SPINK1 and AR in castration-resistant prostate cancer.
Histopathology. 2012 Mar;60(4):645-52. doi: 10.1111/j.1365-2559.2011.04116.x. Epub 2012 Jan 19.
引用本文的文献
1
Biomarkers Associated with Tumor Heterogeneity in Prostate Cancer.
Transl Oncol. 2019 Jan;12(1):43-48. doi: 10.1016/j.tranon.2018.09.003. Epub 2018 Sep 25.
2
The oncogenic transcription factor ERG represses the transcription of the tumour suppressor gene in prostate cancer cells.
Oncol Lett. 2017 Nov;14(5):5605-5610. doi: 10.3892/ol.2017.6841. Epub 2017 Aug 28.
本文引用的文献
1
ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss.
Nat Med. 2013 Aug;19(8):1023-9. doi: 10.1038/nm.3216. Epub 2013 Jun 30.
2
Common gene rearrangements in prostate cancer.
J Clin Oncol. 2011 Sep 20;29(27):3659-68. doi: 10.1200/JCO.2011.35.1916. Epub 2011 Aug 22.
3
An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression.
Cancer Cell. 2010 May 18;17(5):443-54. doi: 10.1016/j.ccr.2010.03.018.
4
Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate.
Nat Genet. 2009 May;41(5):619-24. doi: 10.1038/ng.370. Epub 2009 Apr 26.
5
Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis.
Nat Genet. 2009 May;41(5):524-6. doi: 10.1038/ng.371. Epub 2009 Apr 26.
6
TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation.
Oncogene. 2008 Sep 11;27(40):5348-53. doi: 10.1038/onc.2008.183. Epub 2008 Jun 9.
7
Role of the TMPRSS2-ERG gene fusion in prostate cancer.
Neoplasia. 2008 Feb;10(2):177-88. doi: 10.1593/neo.07822.
8
A causal role for ERG in neoplastic transformation of prostate epithelium.
Proc Natl Acad Sci U S A. 2008 Feb 12;105(6):2105-10. doi: 10.1073/pnas.0711711105. Epub 2008 Feb 1.
9
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.
Science. 2005 Oct 28;310(5748):644-8. doi: 10.1126/science.1117679.
10
Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome.
Oncogene. 2005 May 26;24(23):3847-52. doi: 10.1038/sj.onc.1208518.
Zotero 插件